SMARCB1 and neoplasm: Tazemetostat, an EZH2 inhibitor, is currently under evaluation in different Phase I and II clinical trials in tumours with SMARCB1, SMARCA4 and EZH2 mutations with positive results in patients with different solid tumours [38].